ATE266021T1 - Imidazol-2-carbonsäureamid derivate als raf kinase inhibitoren - Google Patents

Imidazol-2-carbonsäureamid derivate als raf kinase inhibitoren

Info

Publication number
ATE266021T1
ATE266021T1 AT01907980T AT01907980T ATE266021T1 AT E266021 T1 ATE266021 T1 AT E266021T1 AT 01907980 T AT01907980 T AT 01907980T AT 01907980 T AT01907980 T AT 01907980T AT E266021 T1 ATE266021 T1 AT E266021T1
Authority
AT
Austria
Prior art keywords
sub
sup
alkyl
hydrogen
optionally substituted
Prior art date
Application number
AT01907980T
Other languages
English (en)
Inventor
Alessandra Gaiba
Andrew Kenneth Takle
David Matthew Wilson
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE266021T1 publication Critical patent/ATE266021T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01907980T 2000-03-06 2001-03-02 Imidazol-2-carbonsäureamid derivate als raf kinase inhibitoren ATE266021T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0005357.9A GB0005357D0 (en) 2000-03-06 2000-03-06 Compounds
PCT/GB2001/000916 WO2001066540A1 (en) 2000-03-06 2001-03-02 Imidazol-2-carboxamide derivatives as raf kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE266021T1 true ATE266021T1 (de) 2004-05-15

Family

ID=9887051

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01907980T ATE266021T1 (de) 2000-03-06 2001-03-02 Imidazol-2-carbonsäureamid derivate als raf kinase inhibitoren

Country Status (12)

Country Link
US (1) US6987119B2 (de)
EP (1) EP1261602B1 (de)
JP (1) JP2003525937A (de)
AT (1) ATE266021T1 (de)
AU (1) AU2001235844A1 (de)
DE (1) DE60103133T2 (de)
DK (1) DK1261602T3 (de)
ES (1) ES2217118T3 (de)
GB (1) GB0005357D0 (de)
PT (1) PT1261602E (de)
TR (1) TR200401903T4 (de)
WO (1) WO2001066540A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Healthcare Llc .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US7189745B1 (en) 1999-11-22 2007-03-13 Smithkline Beecham Corporation Compounds
DE60103136T2 (de) * 2000-03-06 2004-10-28 Smithkline Beecham Plc, Brentford Imidazolderivate als Raf-Kinase Inhibitoren
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0121494D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
EP1432699A1 (de) * 2001-09-05 2004-06-30 Smithkline Beecham Plc Pyridylfurane und -pyrrole als raf-kinasehemmer
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
EP1432703A1 (de) * 2001-09-05 2004-06-30 Smithkline Beecham Plc Heterocycle-carboxamide derivate als raf kinase inhibitoren
EP2324825A1 (de) 2002-02-11 2011-05-25 Bayer Healthcare LLC Arylharnstoffe mit Angiogenese hemmender Aktivität
AR038966A1 (es) * 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
WO2004019873A2 (en) 2002-08-29 2004-03-11 Scios Inc. Methods of promoting osteogenesis
DE602004007382T2 (de) 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
DK1663978T3 (da) 2003-07-23 2008-04-07 Bayer Pharmaceuticals Corp Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
US20050282909A1 (en) * 2003-11-14 2005-12-22 Diks Sander H Guanylhydrazones in methods of treatment or diagnosis as modulators of signal transduction
MX2007002434A (es) * 2004-08-31 2007-05-04 Astrazeneca Ab Derivados de quinazolinona y su uso como inhibidores de b-raf.
WO2006024836A1 (en) * 2004-09-01 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors
EP1676574A3 (de) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Verfahren zur Förderung des Überlebens von Zell- und Gewebe-Transplantaten
EP1951234A2 (de) * 2005-10-18 2008-08-06 Janssen Pharmaceutica N.V. Verfahren zur hemmung von flt3-kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
EP2016070B1 (de) 2006-04-20 2016-01-13 Janssen Pharmaceutica N.V. Inhibitoren von c-fms-kinase
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP5270553B2 (ja) 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
JP5350247B2 (ja) 2007-08-29 2013-11-27 武田薬品工業株式会社 複素環化合物およびその用途
BRPI0908906A2 (pt) * 2008-03-21 2019-09-24 Novartis Ag compostos heterocíclicos e usos dos mesmos
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
KR20140011780A (ko) * 2012-07-19 2014-01-29 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
EP3046557A1 (de) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in kombination mit mapk-signalweg
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
EP3515446B1 (de) 2016-09-19 2023-12-20 Novartis AG Therapeutische kombinationen mit einem raf-hemmer und einem erk-hemmer
US11266653B2 (en) 2017-05-02 2022-03-08 Novartis Ag Combination therapy
ES3025633T3 (en) 2019-05-13 2025-06-09 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
WO2026041859A1 (en) * 2024-08-19 2026-02-26 Oxford University Innovation Limited Pak1 and/or pak2 activators and their use in the prevention and/or treatment of diseases or conditions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1175431A (en) 1980-07-25 1984-10-02 Alfred Sallmann Tri-substituted imidazole derivatives, processes for their manufacture, pharmaceutical preparations containing them, and their use
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
CA2224563A1 (en) 1995-06-12 1996-12-27 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
DE69637948D1 (de) 1995-10-06 2009-07-23 Merck & Co Inc Substituierte imidazole mit krebsremmender und cytokininhibierender wirkung
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
JP2000504023A (ja) 1996-04-03 2000-04-04 メルク エンド カンパニー インコーポレーテッド 癌治療方法
EP0906307B1 (de) 1996-06-10 2005-04-27 Merck & Co., Inc. Substituierte imidazole mit cytokinin-inhibirender wirkung
WO1998016227A1 (en) 1996-10-15 1998-04-23 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US6040320A (en) 1997-06-30 2000-03-21 Ortho-Mcneil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
ATE257703T1 (de) 1997-10-27 2004-01-15 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
EP1049664B1 (de) 1997-12-22 2005-03-16 Bayer Pharmaceuticals Corporation Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
NZ526958A (en) 1998-05-22 2004-12-24 Smithkline Beecham Corp Novel 2-alkyl substituted imidazole compounds
US7189745B1 (en) 1999-11-22 2007-03-13 Smithkline Beecham Corporation Compounds
WO2002039954A2 (en) 2000-11-20 2002-05-23 Smithkline Beecham Corporation Novel compounds

Also Published As

Publication number Publication date
DK1261602T3 (da) 2004-08-30
US6987119B2 (en) 2006-01-17
EP1261602B1 (de) 2004-05-06
EP1261602A1 (de) 2002-12-04
US20030134837A1 (en) 2003-07-17
DE60103133D1 (de) 2004-06-09
TR200401903T4 (tr) 2004-09-21
PT1261602E (pt) 2004-08-31
AU2001235844A1 (en) 2001-09-17
ES2217118T3 (es) 2004-11-01
JP2003525937A (ja) 2003-09-02
DE60103133T2 (de) 2004-10-14
GB0005357D0 (en) 2000-04-26
WO2001066540A1 (en) 2001-09-13

Similar Documents

Publication Publication Date Title
DE60103133D1 (de) Imidazol-2-carbonsäureamid derivate als raf kinase inhibitoren
ATE266022T1 (de) Imidazol derivate als raf kinase inhibitoren
EP1724262A4 (de) 1-(2h)-isochinolonderivat
EA201170196A1 (ru) Производные бензазепинов и их применение в качестве h3 гистаминовых антагонистов
RU2007110629A (ru) Ингибиторы днк-пк
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
EE200200148A (et) Kinasoliini derivaadid, nende valmistamise meetodning kasutamine
EA200602060A1 (ru) Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
AR036107A1 (es) Derivados de 6-fenilpirrolpirimidindiona, antagonista de los receptores a2 de la adenosina, particularmente del subtipo a2, de aplicacion en la prevencion de la degranulacion de los mastocitos; composiciones farmaceuticas formuladas con dichos compuestos y uso de los mismos en la preparacion de medi
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
TNSN03110A1 (en) Azaindoles.
SE0202463D0 (sv) Novel compounds
HRP20040429B1 (hr) Derivati sulfonamida, njihova priprema i upotrebakao lijekova
EA200600032A1 (ru) Замещённые производные индазолил (индолил) малеимида в качестве ингибиторов киназ
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
DE60206756D1 (de) Purin derivate als a2b adenosin rezeptor antagonisten
NO20082077L (no) Spirosykliske quinazolinderivater som PDE7-inhibitorer
EA200601076A1 (ru) Применение производных n-арилгидразина для борьбы с вредителями
EA200701780A1 (ru) Противоопухолевое средство
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
UA74341C2 (uk) Похідні борелідину, які інгібують ангіогенез
EA200600022A1 (ru) Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций
DK1572198T3 (da) Farmaceutiske forbindelser med alfa2-receptoraktivitet
DK1899331T3 (da) Homomorpholinoxazolidnoner som antibakterielle midler

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1261602

Country of ref document: EP

REN Ceased due to non-payment of the annual fee